Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA - StreetInsider.com

Reuters India

Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA StreetInsider.com Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met ... Biogen pays Ionis $75 million to develop muscle drug after trial successReuters 15 Stocks Moving In Monday's Pre-Market SessionBenzinga Positive results halt Biogen, Ionis trial of SMA drugThe San Diego Union-Tribune all 5 news articles »

Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA - StreetInsider.com
Read More